FDA accelerated approval covers zanidatamab-hrii for HER2-positive biliary tract cancer
The approval applies to previously treated patients with unresectable or metastatic disease whose tumors are HER2-positive by IHC 3+ testing.
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii, marketed as Ziihera by Jazz Pharmaceuticals, Inc., describing it as a bispecific HER2-directed antibody.1
The approval covers previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.1
The FDA record does not provide additional detail on trial data, dosing, or confirmatory trial requirements tied to this accelerated approval.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.